Quoin Pharmaceuticals, Ltd.·4

Dec 3, 5:39 PM ET

Lawlor Sally Bridget 4

4 · Quoin Pharmaceuticals, Ltd. · Filed Dec 3, 2025

Insider Transaction Report

Form 4
Period: 2025-12-01
Lawlor Sally Bridget
Chief Financial Officer
Transactions
  • Award

    Share Option (Right to Buy)

    2025-12-01+10,33010,330 total
    Exercise: $19.36Exp: 2035-12-01ADS (10,330 underlying)
Footnotes (3)
  • [F1]The number of securities underlying the option and the exercise price are listed in terms of American Depositary Shares ("ADSs"). Each ADS represents thirty-five ordinary shares of the Issuer.
  • [F2]The option grant was approved by the Compensation Committee of the Board of Directors of the Issuer on December 1, 2025.
  • [F3]The option vests in four annual installments with 20% vesting on each of December 1, 2026, 2027 and 2028 and 40% vesting on December 1, 2029.

Documents

1 file
  • 4
    tm2532695-1_4seq1.xmlPrimary

    OWNERSHIP DOCUMENT